Related Experiment Video
Updated: Apr 6, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.8K
New Oral Anticoagulants: How Do We Use Them Wisely?
1Department of Neurology, Huashan Hospital, State Key of Laboratory of Neurobiology, Fudan University at Shanghai, No. 12 Mid. Urimuqi Road, Shanghai, 200040, China, drdongyi@yeah.net.
Current Cardiology Reports
|August 5, 2015
Summary
New oral anticoagulants (NOACs) offer stroke prevention for atrial fibrillation patients without frequent blood draws. However, challenges include cost, insurance issues, lack of antidote, and monitoring difficulties.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Background:
- New oral anticoagulants (NOACs) provide alternative stroke prevention for atrial fibrillation (AF).
- Patients appreciate avoiding frequent blood monitoring associated with traditional anticoagulants.
Purpose of the Study:
- To guide clinicians in understanding and wisely selecting NOACs based on indications.
- To discuss practical challenges of NOACs, including cost and reversal strategies.
Main Methods:
- This is a narrative review.
- The review synthesizes existing clinical trial data and practical considerations for NOAC use.
Main Results:
- NOACs demonstrate consistent efficacy and safety across diverse patient populations in clinical trials.
- Key challenges include high cost, variable insurance coverage, absence of a universal antidote, and lack of routine monitoring methods.
Conclusions:
- NOACs represent valuable therapeutic options for AF stroke prevention.
- Addressing challenges related to cost, insurance, antidote availability, and monitoring is crucial for optimal clinical implementation.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
439
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
439
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K